ArticleSmall (Weinheim an der Bergstrasse, Germany)2025
Effects of DNA Origami-Based Nanoagent Design on Apoptosis Induction in a Large 3D Cancer Spheroid Model.
Article in Small (Weinheim an der Bergstrasse, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Programmable Functional Silicification of DNA Origami Nanostructures.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- DNA-Enzyme Hybrid Nanostructures: Functional Materials to Modulate Enzymatic Activity.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Review
- High yield purification of an isoleucine zipper-modified CD95 ligand for efficient cell apoptosis initiation and with biotin or DNA-oligomer binding domain to probe ligand functionalization effects.BMC biotechnology · 2025Article
- Effects of DNA Origami-Based Nanoagent Design on Apoptosis Induction in a Large 3D Cancer Spheroid Model.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
DNA origami offers highly accurate control over shape and addressability on the nanoscale. This precise control makes it highly valuable in various fields, particularly precision nanotherapeutics. For cancer treatment, the extrinsic activation of programmed cell death by Fas receptor (FasR)/CD95-based nanoagents is a promising, minimally invasive strategy. However, treating large, solid tumors poses challenges for the design of DNA origami-based therapeutics, including drug distribution and altered cellular behavior. Here, these challenges are addressed by establishing design principles for nanoagents and testing them in a 3D cancer spheroid model. First, the ability of DNA origami nanostructures are assessed to penetrate large cancer spheroids, finding that penetration is influenced by the DNA origami size rather than its structural flexibility. Second, the capability of FasL-DNA origami-based nanoagents are evaluated to induce apoptosis in cancer spheroids, representing a more biologically relevant environment, compared to 2D studies. It is found that apoptosis induction is primarily determined by the FasL attachment strategy rather than the underlying DNA origami structure. The most effective nanoagents constructed in this study halted spheroid growth and eradicated all cancer cells within the spheroids. This study offers important insights into critical design considerations for DNA-based therapeutics for complex cellular environments, advancing DNA origami nanotherapeutic development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.